Author

F. I. Thege

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:spatial transcriptomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

A. Maitra· 3 shared C. M. Schmidt· 2 shared J. Min· 2 shared K. I. Rajapakshe· 2 shared M. P. Kim· 2 shared M. Sans· 2 shared M. W. Hurd· 2 shared M. Yip-Schneider· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Maitra

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintAug 14, 2023

Integrated spatial transcriptomics and lipidomics of precursor lesions of pancreatic cancer identifies enrichment of long chain sulfatide biosynthesis as an early metabolic alteration

M. Sans, Y. Chen, F. I. Thege…·J. F. Fahrmann

DOI 10.1101/2023.08.14.553002

𝕏 PostBluesky

Cancer BiologyCancer DiscoveryPeer-reviewedJun 7, 2023

Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential

M. Sans, Y. Makino, J. Min…·A. Maitra

This study identifies NKX6-2 as a driver of gastric differentiation in IPMNs, linking its expression to indolent biological potential and progression.

DOI 10.1158/2159-8290.cd-22-1200

𝕏 PostBluesky

Cancer BiologybioRxivPreprintDec 9, 2021

Programmable in vivo CRISPR activation elucidates the oncogenic and immunosuppressive role of MYC in lung adenocarcinoma

F. I. Thege, D. N. Rupani, B. B. Bharati…·S. M. Woermann

This study uses CRISPR activation to show MYC promotes lung cancer growth and creates an immunosuppressive tumor environment, suggesting combined MYC/immune therapies could benefit patients.

DOI 10.1101/2021.12.09.471859

mousebulk RNA-seq

𝕏 PostBluesky